US 12,227,763 B2
Methods and compositions for treating cancer
Jonathan Alexander Terrett, Cambridge, MA (US); Demetrios Kalaitzidis, Cambridge, MA (US); Mary-Lee Dequéant, Cambridge, MA (US); and Zinkal Samir Padalia, Cambridge, MA (US)
Assigned to CRISPR Therapeutics AG, Zug (CH)
Appl. No. 17/054,483
Filed by CRISPR Therapeutics AG, Zug (CH)
PCT Filed May 10, 2019, PCT No. PCT/IB2019/000500
§ 371(c)(1), (2) Date Nov. 10, 2020,
PCT Pub. No. WO2019/215500, PCT Pub. Date Nov. 14, 2019.
Claims priority of provisional application 62/826,600, filed on Mar. 29, 2019.
Claims priority of provisional application 62/773,658, filed on Nov. 30, 2018.
Claims priority of provisional application 62/756,643, filed on Nov. 7, 2018.
Claims priority of provisional application 62/701,340, filed on Jul. 20, 2018.
Claims priority of provisional application 62/670,417, filed on May 11, 2018.
Prior Publication US 2021/0060072 A1, Mar. 4, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 5/0783 (2010.01); A61K 39/00 (2006.01); A61K 47/68 (2017.01); A61K 51/10 (2006.01); A61P 35/00 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C07K 14/74 (2006.01); C07K 16/28 (2006.01); C12N 9/22 (2006.01); C12N 15/11 (2006.01); C12N 15/86 (2006.01); A61K 38/00 (2006.01)
CPC C12N 5/0636 (2013.01) [A61K 39/4611 (2023.05); A61K 39/4631 (2023.05); A61K 39/464411 (2023.05); A61K 39/464412 (2023.05); A61K 39/464417 (2023.05); A61K 39/464438 (2023.05); A61K 47/6849 (2017.08); A61K 51/1027 (2013.01); A61P 35/00 (2018.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70521 (2013.01); C07K 14/70539 (2013.01); C07K 14/70578 (2013.01); C07K 16/2803 (2013.01); C07K 16/2875 (2013.01); C07K 16/2878 (2013.01); C12N 9/22 (2013.01); C12N 15/11 (2013.01); C12N 15/86 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); A61K 2239/26 (2023.05); A61K 2239/28 (2023.05); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/74 (2013.01); C07K 2317/76 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01); C12N 2310/20 (2017.05); C12N 2510/00 (2013.01); C12N 2750/14143 (2013.01); C12N 2800/80 (2013.01)] 9 Claims
 
1. A method comprising administering to a subject a population of cells comprising engineered T cells, wherein the engineered T cells comprise:
(i) a disrupted TRAC gene;
(ii) a disrupted β2M gene;
(iii) a disrupted CD70 gene; and
(iv) a nucleic acid encoding a CAR that binds CD70, wherein the disrupted TRAC gene comprises the nucleic acid encoding the CAR;
wherein the subject has cancer, wherein the cancer is a solid tumor malignancy, and wherein the cancer expresses CD70.